On November 19, 2020, the Company issued 733,000 restricted stock units (“RSUs”) at a weighted average grant date fair value of $13.78, all of which are subject to vesting. These units will vest ratably over a four-year period commencing on the first anniversary of the grant date. Non-cash equity-based compensation expense associated with the grant will be approximately $8.9 over the requisite service period.

On November 19, 2020, the Company issued 686,000 stock options at a weighted average exercise price of $13.78 and a weighted average grant date fair value of $6.71. These options will vest and become exercisable ratably over a four-year period commencing on the first anniversary of the grant date. Non-cash equity-based compensation expense associated with the grant will be approximately $4.1 over the requisite service period.

Information regarding the total equity-based compensation expense, for the periods indicated is as follows:

Three Months Ended

December 31,

2020

2019

Total equity-based compensation expense recognized

4.9

8.2

At December 31, 2020 the aggregate unamortized value of outstanding stock-based compensation awards was approximately $37.6, with a weighted average remaining life of 1.4 years.

The Company’s stockholders have approved the Company’s 2018 Employee Stock Purchase Plan (the “ESPP”). A total of 1,100,000 shares of the Company’s common stock were made available for sale on October 22, 2018, of which 172,000 were issued on November 14, 2019 and 120,000 were issued on November 16, 2020. An additional portion thereof is expected to be issued in November 2021.